Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570099 | 1.00 | MAPT (0.58) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL3973537 | 0.90 | MAPT (0.69) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL10714696 | 0.85 | TDP1 (0.63) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL30255693 | 0.85 | TDP1 (0.81) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL653911 | 0.85 | TDP1 (0.81) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL13735059 | 0.84 | MAPT (0.56) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL20788508 | 0.84 | MAPT (0.56) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL8587439 | 0.84 | MAPT (0.56) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL1663325 | 0.82 | CRHBP (0.63) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL13735401 | 0.82 | MAPT (0.55) | MAPTTDP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | claimed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-3184522-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-01-11 | — | — | EP | disclosed |
| US-11322695-B2 | Ink composition for organic light-emitting device, organic light-emitting device including film formed by using the ink composition, and method of manufacturing the organic light-emitting device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20200295273-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-09-17 | — | — | US | disclosed |
| US-10597403-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, organic light-emitting device including the condensed cyclic compound, and method of manufacturing the organic light-emitting device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-03-24 | — | — | US | disclosed |
| EP-3269783-B1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-10-16 | — | — | EP | disclosed |
| US-20180019411-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-01-18 | — | — | US | disclosed |
| US-20180019411-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-01-18 | — | — | US | disclosed |
| EP-3269783-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd (KR) | 2018-01-17 | — | — | EP | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009020768-A1 | TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | MAPT 4212/4885TDP1 3005/4885MEN1 2170/4885 |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | MAPT 2110/4885TDP1 926/4885MEN1 2635/4885 |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | MAPT 3462/4885TDP1 3263/4885MEN1 3722/4885 |
| US-10597403-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, organic light-emitting device including the condensed cyclic compound, and method of manufacturing the organic light-emitting device | CRY1, C9, CRY2 | MAPT 1416/4885TDP1 2480/4885MEN1 623/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | MAPT 4097/4885TDP1 3004/4885MEN1 2339/4885 |
| US-11322695-B2 | Ink composition for organic light-emitting device, organic light-emitting device including film formed by using the ink composition, and method of manufacturing the organic light-emitting device | TYR, IK, TH | MAPT 173/4885TDP1 947/4885MEN1 2845/4885 |
| US-20180019411-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | TYR, LEF1, CYP1A1 | MAPT 202/4885TDP1 509/4885MEN1 2605/4885 |
| US-20200295273-A1 | INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE | TYR, IK, TH | MAPT 173/4885TDP1 947/4885MEN1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.